DHRS2 Polyclonal Antibody

Total Page：16

File Type：pdf, Size：1020Kb

PRODUCT DATA SHEET Bioworld Technology,Inc. DHRS2 polyclonal antibody Catalog: BS8526 Host: Rabbit Reactivity: Human,Mouse,Rat BackGround: IF: 1:50~1:200 DHRS2 (dehydrogenase/reductase (SDR family) member Storage&Stability: 2), also known as SDR25C1 or HEP27, is a 258 amino Store at 4°C short term. Aliquot and store at -20°C long acid protein that localizes to the nucleus and belongs to term. Avoid freeze-thaw cycles. the short-chain dehydrogenase/reductase (SDR) family. Specificity: Functioning as an NADPH-dependent dicarbonyl reduc- DHRS2 polyclonal antibody detects endogenous levels of tase, DHRS2 is thought to inhibit cell replication by ei- DHRS2 protein. ther converting cortisone in cortisol, or by catalyzing the DATA: oxidation of androgen and estrogen. The gene encoding DHRS2 maps to human chromosome 14, which houses over 700 genes and comprises nearly 3.5% of the human genome. Chromosome 14 encodes the presinilin 1 (PSEN1) gene, which is one of the three key genes asso- ciated with the development of Alzheimer's disease (AD). The SERPINA1 gene is also located on chromosome 14 and, when defective, leads to the genetic disorder Western blot analysis of extracts of various cell lines, using DHRS2 an- α1-antitrypsin deficiency, which is characterized by se- tibody. vere lung complications and liver dysfunction. Product: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Molecular Weight: ~ 33 kDa Swiss-Prot: Q13268 Immunofluorescence analysis of HeLa cell using DHRS2 antibody. Purification&Purity: Blue: DAPI for nuclear staining. The antibody was affinity-purified from rabbit antiserum Note: by affinity-chromatography using epitope-specific im- For research use only, not for use in diagnostic procedure. munogen and the purity is > 95% (by SDS-PAGE). Applications: WB: 1:500~1:2000 IHC: 1:50~1:200 Bioworld Technology, Inc. Bioworld technology, co. Ltd. Add： 1660 South Highway 100, Suite 500 St. Louis Park, Add： No 9, weidi road Qixia District Nanjing, 210046, MN 55416,USA. P. R. China. Email: [email protected] Email: [email protected] Tel: 6123263284 Tel: 0086-025-68037686 Fax: 6122933841 Fax: 0086-025-68035151 .

Copy Link

Recommended publications

DHRS2 Polyclonal Antibody Product Information
DHRS2 Polyclonal Antibody Cat #: ABP51170 Size: 30μl /100μl /200μl Product Information Product Name: DHRS2 Polyclonal Antibody Applications: WB, ELISA Isotype: Rabbit IgG Reactivity: Human, Mouse Catalog Number: ABP51170 Lot Number: Refer to product label Formulation: Liquid Concentration: 1 mg/ml Storage: Store at -20°C. Avoid repeated Note: Contain sodium azide. freeze / thaw cycles. Background: DHRS2 (dehydrogenase/reductase (SDR family) member 2), also known as SDR25C1 or HEP27, is a 258 amino acid protein that localizes to the nucleus and belongs to the short-chain dehydrogenase/reductase (SDR) family. Functioning as an NADPH-dependent dicarbonyl reductase, DHRS2 is thought to inhibit cell replication by either converting cortisone in cortisol, or by catalyzing the oxidation of androgen and estrogen. The gene encoding DHRS2 maps to human chromosome 14, which houses over 700 genes and comprises nearly 3.5% of the human genome. Chromosome 14 encodes the presinilin 1 (PSEN1) gene, which is one of the three key genes associated with the development of Alzheimer's disease (AD). The SERPINA1 gene is also located on chromosome 14 and, when defective, leads to the genetic disorder α1- antitrypsin deficiency, which is characterized by severe lung complications and liver dysfunction. Application Notes: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), ELISA (1:40000). Not yet tested in other applications. Storage Buffer: PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. Storage Instructions: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
[Show full text]
Improved Detection of Gene Fusions by Applying Statistical Methods Reveals New Oncogenic RNA Cancer Drivers
bioRxiv preprint doi: https://doi.org/10.1101/659078; this version posted June 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Improved detection of gene fusions by applying statistical methods reveals new oncogenic RNA cancer drivers Roozbeh Dehghannasiri1, Donald Eric Freeman1,2, Milos Jordanski3, Gillian L. Hsieh1, Ana Damljanovic4, Erik Lehnert4, Julia Salzman1,2,5* Author affiliation 1Department of Biochemistry, Stanford University, Stanford, CA 94305 2Department of Biomedical Data Science, Stanford University, Stanford, CA 94305 3Department of Computer Science, University of Belgrade, Belgrade, Serbia 4Seven Bridges Genomics, Cambridge, MA 02142 5Stanford Cancer Institute, Stanford, CA 94305 *Corresponding author [email protected] Short Abstract: The extent to which gene fusions function as drivers of cancer remains a critical open question. Current algorithms do not sufficiently identify false-positive fusions arising during library preparation, sequencing, and alignment. Here, we introduce a new algorithm, DEEPEST, that uses statistical modeling to minimize false-positives while increasing the sensitivity of fusion detection. In 9,946 tumor RNA-sequencing datasets from The Cancer Genome Atlas (TCGA) across 33 tumor types, DEEPEST identifies 31,007 fusions, 30% more than identified by other methods, while calling ten-fold fewer false-positive fusions in non-transformed human tissues. We leverage the increased precision of DEEPEST to discover new cancer biology. For example, 888 new candidate oncogenes are identified based on over-representation in DEEPEST-Fusion calls, and 1,078 previously unreported fusions involving long intergenic noncoding RNAs partners, demonstrating a previously unappreciated prevalence and potential for function.
[Show full text]
Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte As Tumorigenic Precursor and DMRT1 As Candidate Chromosome 9 Gene
Research Article Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene Leendert H.J. Looijenga,1 Remko Hersmus,1 Ad J.M. Gillis,1 Rolph Pfundt,4 Hans J. Stoop,1 Ruud J.H.L.M. van Gurp,1 Joris Veltman,1 H. Berna Beverloo,2 Ellen van Drunen,2 Ad Geurts van Kessel,4 Renee Reijo Pera,5 Dominik T. Schneider,6 Brenda Summersgill,7 Janet Shipley,7 Alan McIntyre,7 Peter van der Spek,3 Eric Schoenmakers,4 and J. Wolter Oosterhuis1 1Department of Pathology, Josephine Nefkens Institute; Departments of 2Clinical Genetics and 3Bioinformatics, Erasmus Medical Center/ University Medical Center, Rotterdam, the Netherlands; 4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; 5Howard Hughes Medical Institute, Whitehead Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts; 6Clinic of Paediatric Oncology, Haematology and Immunology, Heinrich-Heine University, Du¨sseldorf, Germany; 7Molecular Cytogenetics, Section of Molecular Carcinogenesis, The Institute of Cancer Research, Sutton, Surrey, United Kingdom Abstract histochemistry, DMRT1 (a male-specific transcriptional regulator) was identified as a likely candidate gene for Spermatocytic seminomas are solid tumors found solely in the involvement in the development of spermatocytic seminomas. testis of predominantly elderly individuals. We investigated these tumors using a genome-wide analysis for structural and (Cancer Res 2006; 66(1): 290-302) numerical chromosomal changes through conventional kar- yotyping, spectral karyotyping, and array comparative Introduction genomic hybridization using a 32 K genomic tiling-path Spermatocytic seminomas are benign testicular tumors that resolution BAC platform (confirmed by in situ hybridization).
[Show full text]
Microarray Bioinformatics and Its Applications to Clinical Research
Microarray Bioinformatics and Its Applications to Clinical Research A dissertation presented to the School of Electrical and Information Engineering of the University of Sydney in fulfillment of the requirements for the degree of Doctor of Philosophy i JLI ··_L - -> ...·. ...,. by Ilene Y. Chen Acknowledgment This thesis owes its existence to the mercy, support and inspiration of many people. In the first place, having suffering from adult-onset asthma, interstitial cystitis and cold agglutinin disease, I would like to express my deepest sense of appreciation and gratitude to Professors Hong Yan and David Levy for harbouring me these last three years and providing me a place at the University of Sydney to pursue a very meaningful course of research. I am also indebted to Dr. Craig Jin, who has been a source of enthusiasm and encouragement on my research over many years. In the second place, for contexts concerning biological and medical aspects covered in this thesis, I am very indebted to Dr. Ling-Hong Tseng, Dr. Shian-Sehn Shie, Dr. Wen-Hung Chung and Professor Chyi-Long Lee at Change Gung Memorial Hospital and University of Chang Gung School of Medicine (Taoyuan, Taiwan) as well as Professor Keith Lloyd at University of Alabama School of Medicine (AL, USA). All of them have contributed substantially to this work. In the third place, I would like to thank Mrs. Inge Rogers and Mr. William Ballinger for their helpful comments and suggestions for the writing of my papers and thesis. In the fourth place, I would like to thank my swim coach, Hirota Homma.
[Show full text]
Associations of Single Nucleotide Polymorphisms with Mucinous Colorectal Cancer: Genome-Wide Common Variant and Gene-Based Rare Variant Analyses Michelle E
Penney et al. Biomarker Research (2018) 6:17 https://doi.org/10.1186/s40364-018-0133-z RESEARCH Open Access Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses Michelle E. Penney1, Patrick S. Parfrey2, Sevtap Savas1,3 and Yildiz E. Yilmaz1,2,4* Abstract Background: Colorectal cancer has significant impact on individuals and healthcare systems. Many genes have been identified to influence its pathogenesis. However, the genetic basis of mucinous tumor histology, an aggressive subtype of colorectal cancer, is currently not well-known. This study aimed to identify common and rare genetic variations that are associated with the mucinous tumor phenotype. Methods: Genome-wide single nucleotide polymorphism (SNP) data was investigated in a colorectal cancer patient cohort (n = 505). Association analyses were performed for 729,373 common SNPs and 275,645 rare SNPs. Common SNP association analysis was performed using univariable and multivariable logistic regression under different genetic models. Rare-variant association analysis was performed using a multi-marker test. Results: No associations reached the traditional genome-wide significance. However, promising genetic associations were identified. The identified common SNPs significantly improved the discriminatory accuracy of the model for mucinous tumor phenotype. Specifically, the area under the receiver operating characteristic curve increased from 0.703 (95% CI: 0.634–0.773) to 0.916 (95% CI: 0.873–0.960) when considering the most significant SNPs. Additionally, the rare variant analysis identified a number of genetic regions that potentially contain causal rare variants associated with the mucinous tumor phenotype. Conclusions: This is the first study applying both common and rare variant analyses to identify genetic associations with mucinous tumor phenotype using a genome-wide genotype data.
[Show full text]
A Genomic View of Estrogen Actions in Human Breast Cancer Cells by Expression Profiling of the Hormone-Responsive Transcriptome
719 A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome Luigi Cicatiello1, Claudio Scafoglio1, Lucia Altucci1, Massimo Cancemi1, Guido Natoli1, Angelo Facchiano2, Giovanni Iazzetti3, Raffaele Calogero4, Nicoletta Biglia6, Michele De Bortoli5,7, Christian Sfiligoi7, Piero Sismondi6,7, Francesco Bresciani1 and Alessandro Weisz1 1Dipartimento di Patologia generale, Seconda Università degli Studi di Napoli, Vico L. De Crecchio 7, 80138 Napoli, Italy 2Istituto di Scienze dell’Alimentazione del Consiglio Nazionale delle Ricerche, Avellino, Italy 3Dipartimento di Genetica, Biologia generale e molecolare, Università di Napoli ‘Federico II’, Napoli, Italy 4Dipartimento di Scienze cliniche e biologiche, Università degli Studi di Torino, Torino, Italy 5Dipartimento di Scienze oncologiche, Università degli Studi di Torino, Torino, Italy 6Dipartimento di Discipline ostetriche e ginecologiche, Università degli Studi di Torino, Torino, Italy 7Laboratorio di Ginecologia oncologica, Istituto per la Ricerca e la Cura del Cancro, Candiolo, Italy (Requests for offprints should be addressed to A Weisz; Email: [email protected]) Abstract Estrogen controls key cellular functions of responsive cells including the ability to survive, replicate, communicate and adapt to the extracellular milieu. Changes in the expression of 8400 genes were monitored here by cDNA microarray analysis during the first 32 h of human breast cancer (BC) ZR-75·1 cell stimulation with a mitogenic dose of 17-estradiol, a timing which corresponds to completion of a full mitotic cycle in hormone-stimulated cells. Hierarchical clustering of 344 genes whose expression either increases or decreases significantly in response to estrogen reveals that the gene expression program activated by the hormone in these cells shows 8 main patterns of gene activation/inhibition.
[Show full text]
Datasheet Blank Template
SAN TA C RUZ BI OTEC HNOL OG Y, INC . DHRS2 (1F10): sc-517054 BACKGROUND APPLICATIONS DHRS2 (dehydrogenase/reductase (SDR family) member 2), also known as DHRS2 (1F10) is recommended for detection of DHRS2 of human origin by SDR25C1 or HEP27, is a 258 amino acid protein that localizes to the nucleus Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), and belongs to the short-chain dehydrogenase/reductase (SDR) family. Func - immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell tioning as an NADPH-dependent dicarbonyl reductase, DHRS2 is thought to lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30- inhibit cell replication by either converting cortisone in cortisol, or by catalyz - 1:3000). ing the oxidation of androgen and estrogen. The gene encoding DHRS2 maps Suitable for use as control antibody for DHRS2 siRNA (h): sc-92153, DHRS2 to human chromosome 14, which houses over 700 genes and comprises nearly shRNA Plasmid (h): sc-92153-SH and DHRS2 shRNA (h) Lentiviral Particles: 3.5% of the human genome. Chromosome 14 encodes the presinilin 1 (PSEN1) sc-92153-V. gene, which is one of the three key genes associated with the development of Alzheimer’s disease (AD). The SERPINA1 gene is also located on chromo - Molecular Weight of DHRS2: 28 kDa. some 14 and, when defective, leads to the genetic disorder α1-antitrypsin deficiency, which is characterized by severe lung complications and liver RECOMMENDED SUPPORT REAGENTS dys function. To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP REFERENCES (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ 1.
[Show full text]
Détermination D'une Signature Transcriptionnelle De L'état De
UNIVERSITÉ DE NANTES FACULTE DE MÉDECINE DÉTERMINATION D’UNE SIGNATURE TRANSCRIPTIONNELLE SANGUINE DU DEVENIR À LONG TERME DU GREFFON DE PATIENTS RECEVANT UNE ALLOGREFFE RÉNALE. THESE DE DOCTORAT École doctorale : CHIMIE-BIOLOGIE Discipline : SCIENCES DE LA VIE ET DE LA SANTE Spécialité : IMMUNOLOGIE Présentée et soutenue publiquement par Christophe BRAUD le 20 décembre 2007, devant le jury ci-dessous : Rapporteurs : Eric THERVET ; Professeur ; Paris Alberto SANCHEZ-FUEYO ; Docteur ; Barcelone Examinateurs : Dominique BAETEN ; Professeur ; Amsterdam Georges GUELLAEN ; Directeur de recherche ; Paris Jean-Paul SOULILLOU ; Professeur ; Nantes Directeur de thèse : Dr. Sophie BROUARD ; Chargé de recherche ; Nantes « Ce n’est pas parce que les choses sont difficiles que nous n’osons pas, c’est parce que nous n’osons pas qu’elles sont difficiles » Sénèque « Le futur appartient à ceux qui croient à la beauté de leurs rêves » Eleanor Roosevelt Sommaire Sommaire Sommaire ................................................................................................................................... 3 Abréviations ............................................................................................................................... 5 Liste des figures ......................................................................................................................... 6 Liste des tables ........................................................................................................................... 7 Avant-propos .............................................................................................................................
[Show full text]
Mrna-Mirna-Lncrna Regulatory Network in Nonalcoholic Fatty Liver Disease
International Journal of Molecular Sciences Article mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease Marwa Matboli 1,* , Shaimaa H. Gadallah 2 , Wafaa M. Rashed 3 , Amany Helmy Hasanin 4, Nada Essawy 5, Hala M. Ghanem 2 and Sanaa Eissa 1,* 1 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo 11382, Egypt 2 Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo 11382, Egypt; [email protected] (S.H.G.); [email protected] (H.M.G.) 3 Department of Research, Children’s Cancer Hospital-57357, Cairo 11382, Egypt; [email protected] 4 Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo 11382, Egypt; [email protected] 5 Institut Pasteur, CEDEX 15, 75724 Paris, France; [email protected] * Correspondence: [email protected] (M.M.); [email protected] (S.E.) Abstract: Aim: we aimed to construct a bioinformatics-based co-regulatory network of mRNAs and non coding RNAs (ncRNAs), which is implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), followed by its validation in a NAFLD animal model. Materials and Methods: The mRNAs–miRNAs–lncRNAs regulatory network involved in NAFLD was retrieved and constructed utilizing bioinformatics tools. Then, we validated this network using an NAFLD animal model, high sucrose and high fat diet (HSHF)-fed rats. Finally, the expression level of the network players was assessed in the liver tissues using reverse transcriptase real-time polymerase chain reaction. Results: in-silico constructed network revealed six mRNAs (YAP1, FOXA2, AMOTL2, TEAD2, SMAD4 and Citation: Matboli, M.; Gadallah, S.H.; NF2), two miRNAs (miR-650 and miR-1205), and two lncRNAs (RPARP-AS1 and SRD5A3-AS1) that Rashed, W.M.; Hasanin, A.H.; Essawy, play important roles as a co-regulatory network in NAFLD pathogenesis.
[Show full text]
DHRS2 Mediates Cell Growth Inhibition Induced by Trichothecin
Luo et al. Journal of Experimental & Clinical Cancer Research (2019) 38:300 https://doi.org/10.1186/s13046-019-1301-1 RESEARCH Open Access DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma Xiangjian Luo1,2,3,4*, Namei Li1,2,3†, Xu Zhao1,2,3†, Chaoliang Liao1,2,3, Runxin Ye1,2,3, Can Cheng1,2,3, Zhijie Xu5, Jing Quan1,2,3, Jikai Liu6 and Ya Cao1,2,3,4 Abstract Background: Cancer is fundamentally a deregulation of cell growth and proliferation. Cancer cells often have perturbed metabolism that leads to the alteration of metabolic intermediates. Dehydrogenase/reductase member 2 (DHRS2) belongs to short-chain alcohol dehydrogenase/reductase (SDR) superfamily, which is functionally involved in a number of intermediary metabolic processes and in the metabolism of lipid signaling molecules. DHRS2 displays closely association with the inhibition of cell proliferation, migration and quiescence in cancers. Methods: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium (MTS), 5-ethynyl-2′- deoxyuridine (EdU) and colony formation assays were applied to evaluate the proliferative ability of nasopharyngeal carcinoma (NPC) cells. We performed lipid metabolite profiling using gas chromatography coupled with mass spectrometry (GC/MS) to identify the proximal metabolite changes linked to DHRS2 overexpression. RNA sequencing technique combined with differentially expressed genes analysis was applied to identify the expression of genes responsible for the anti-tumor effect of trichothecin (TCN), a natural sesquiterpenoid compound isolated from an endophytic fungus. Results: Our current findings reveal that DHRS2 affects lipid metabolite profiling to induce cell cycle arrest and growth inhibition in NPC cells.
[Show full text]
Forkhead Box R1-Mediated Stress Response Linked to a Case of Human Microcephaly and Brain Atrophy
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.03.366740; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Forkhead box R1-mediated stress response linked to a case of human microcephaly and brain atrophy Andressa Mota1, Rui Hong1, 2, Sheng-Yong Niu, Féodora L. Bertherat1, Lynne Wolfe3, Christine May Malicdan3, Thomas C. Markello3, David R. Adams3, William A. Gahl3, Christine Cheng1, 2, Uwe Beffert1 and Angela Ho1 1Department of Biology, Boston University, 24 Cummington Mall, Boston, MA 02215, USA 2Bioinformatics Program, Boston University, 24 Cummington Mall, Boston, MA 02215, USA 3NIH Undiagnosed Diseases Program, Common Fund, Office of the Director, National Institutes of Health, and National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. Correspondence: [email protected] (U.B.), [email protected] (A.H.) Lead Contact: [email protected] (A.H.) Running title: FOXR1 M280L variant leads to impaired FOXR1 function 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.03.366740; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract (175 words) Forkhead box (Fox) family transcription factors are highly conserved and play essential roles in a wide range of cellular and developmental processes. We report an individual with severe neurological symptoms including postnatal microcephaly, progressive brain atrophy and global developmental delay associated with a de novo missense variant (M280L) in the FOXR1 gene.
[Show full text]
Using Intrinsic and Extrinsic Methods to Engineer Improved Expression of Recombinant Proteins and Retroviral Vectors in Mammalian Cells
USING INTRINSIC AND EXTRINSIC METHODS TO ENGINEER IMPROVED EXPRESSION OF RECOMBINANT PROTEINS AND RETROVIRAL VECTORS IN MAMMALIAN CELLS By Sarah Inwood A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July 2018 © 2018 Sarah Inwood All Rights Reserved Abstract Recombinant proteins, produced by introducing DNA into producer cells, are important in biotechnology, pharmaceuticals and academia. While prokaryotic cells are still most commonly used in these fields, mammalian cells are becoming more prevalent, especially for human proteins such antibodies, due to their inherent ability to correctly fold proteins, and retroviral vectors, due to their viral pseudotyping. This dissertation focuses on engineering improvement of recombinant protein expression and retroviral vector titer using both intrinsic methods such as cell engineering and extrinsic methods such as process development. To this end, multiple strategies such as non-coding RNA, stable transfections, CRISPR/Cas9 knockout, high-throughput screenings, and bioreactor perfusion processes were employed. Retroviral vectors have been of interest for some time due to their ability to modify genomes with relative ease and safety. This is increasingly so with the advancement of adoptive T-cell therapy, which is the transfer of T-Cells into a patient. These T-cells, often autologous, are typically modified, via various methods including retroviral vectors. Using mir-22-3p, which improves recombinant protein production, the first strategy was to identify gene targets of this microRNA that also improve recombinant protein expression. A microarray analysis was followed by bioinformatics; combining the results of the microarray with the predicted microRNA targets and the results of a high-throughput siRNA screen.
[Show full text]